Multiple sclerosis (MS), especially in its early stages, shares overlapping symptoms with many other conditions. Unfortunately, this makes it easy to misdiagnose. One of these conditions, which is gaining attention in the medical community, is vitamin B12 deficiency.
Multiple Sclerosis–Cause Unknown
Multiple sclerosis, on the other hand, is thought to be an autoimmune disorder in which the immune system attacks the central nervous system, damaging the protective myelin sheath that surrounds nerve fibers (a process known as demyelination). This damage results in scar tissue (sclerosis) around the nerve fibers, and disrupted communication between the brain and other parts of the body.Researchers have suspected a connection between multiple sclerosis (MS) and vitamin B12 deficiency for decades, due to the similarity of neurological symptoms that are common to both conditions, such as muscle weakness, numbness, tingling, fatigue, and cognitive dysfunction. Also, being deficient in vitamin B12 is considered a risk factor for MS. However, studies attempting to confirm a direct relationship between the two have been inconsistent. There are numerous other possible causes of MS, such as viruses, autoimmune diseases, and environmental factors. The exact cause, or causes, of MS, are unknown.
Link Between B12 Deficiency and MS
A recent study, conducted by researchers from Sanford Burnham Prebys, in collaboration with others, and published in the December 2023 issue of Cell Reports, sheds more light on the subject, revealing a molecular link between vitamin B12 deficiency and multiple sclerosis. The researchers suggest the possibility of new ways to treat MS via specific brain-targeting B12 formulations.“Our study provides a molecular link between MS and vitamin B12 in the brain. This link is accessed by the MS drug fingolimod (Gilenya)—known as an S1P receptor modulator—that was found to enhance vitamin B12 entry into brain cells (called astrocytes) while concomitantly reducing neuroinflammation. For MS patients, these results support treatments that could increase the brain’s vitamin B12 levels, especially if they are using S1P receptor modulator therapy.”The study also noted the significant fact that levels of the B12 receptor CD320 are known to be reduced in MS plaques and that lower levels of CD320, or a dietary restriction of B12, worsened the disease course in animal models and reduced the effectiveness of fingolimod.
B12 for the Brain
While vitamin B12 supplementation has generally been recommended only for those MS patients who have been found to be deficient, this study highlights the importance of B12 for the brain, even when blood levels appear within a normal range, and offers hope for the development of specific, brain-targeted B12 therapies.“B12 deficiency as determined by blood tests can share signs and symptoms associated with MS. However, blood tests can not directly assess the brain’s vitamin B12 levels. Our study implicates reduced B12 in the brains of MS patients as another variable that could be corrected by B12 supplementation—possibly not detected by blood levels—especially in conjunction with S1P receptor modulator therapies (we used fingolimod, known commercially as Gilenya), and this may be even more critical in patients with evidence of B12 deficiency as well as those with normal blood levels but who may have unappreciated B12 deficiency within the brain.